Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis.
The pharmacokinetics of albendazole and its main metabolite, albendazole sulphoxide, have been examined after giving a single oral dose of 200 mg albendazole to 19 patients with either Echinococcus multilocularis or E. granulosus, 5 of whom had significant extrahepatic obstruction due to the underlying disease. The AUC of albendazole sulphoxide was increased in the latter patients (mean 122 mumols.h.l-1 compared to 17 mumols.h.l-1 in the non-obstructed group). Obstructed patients had delayed absorption, ka averaging 0.39 compared to 1.41 h-1 in non-obstructed patients. The corresponding elimination rate constant, ke was also prolonged, averaging 0.041 and 0.13 h-1 in the two groups, respectively. Four patients were restudied after complete or partial resolution of the cholestasis. The pharmacokinetic parameters in them had returned towards values comparable to those in the non-obstructed patients.
Cotting
J
J
Department of Clinical Pharmacology, University of Berne, Switzerland.
Zeugin
T
T
Steiger
U
U
Reichen
J
J
D000328:Adult; D000368:Aged; D015766:Albendazole / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics*; D002779:Cholestasis / Q000378:metabolism*; D004443:Echinococcosis / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged
D015766:Albendazole; C027186:albendazole sulfoxide